Breast Cancer Clinical Trials in Boston, MA

Breast Cancer Clinical Trials in Boston, MA

View the best 10 breast cancer medical studies in Boston, Massachusetts. Access promising new therapies by applying to a Boston-based Breast Cancer clinical trial.

Trials in Boston, Massachusetts

Here are the top 10 medical studies for breast cancer in Boston, Massachusetts

Image of Baptist MD Anderson Cancer Center in Jacksonville, United States.

Breast Cancer Locator (BCL) guided partial mastectomy +1 More

Procedure

Recruiting1 award9 criteria
This trial is designed to compare the safety and effectiveness of two methods for guiding breast cancer surgery.
Image of Research Site in Scottsdale, United States.

Trastuzumab Deruxtecan

Monoclonal Antibodies

Recruiting2 awardsPhase 3
This trial is testing a new drug called trastuzumab deruxtecan for patients with advanced breast cancer that hasn't responded to other treatments. The drug works by specifically targeting and killing cancer cells. The study aims to see if this drug helps patients live longer or improves their quality of life compared to other treatments. Trastuzumab deruxtecan has shown significant clinical benefits in treating advanced breast cancer and other similar tumors.
Image of Florida Cancer Specialists South - SCRI - PPDS in Sarasota, United States.

H3B-6545 +1 More

Protein Degrader

Recruiting1 awardPhase 1
This trial is testing a combination of two drugs to treat estrogen receptor-positive breast cancer. The goal is to find the maximum tolerated dose and/or the recommended Phase 2 dose of the combination.
Image of Brigham & Women's Hospital in Boston, United States.

Viewray MRIdian® Linac

Radiation Therapy

Recruiting1 award5 criteria
This trial is testing a new cancer treatment that uses MRI to target radiation.
Image of Beth Israel Deaconess Medical Center in Boston, United States.

SGN-B6A

Monoclonal Antibodies

Recruiting1 awardPhase 1
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Image of VA Boston Healthcare System in Boston, United States.

Polygenic risk score (PRS)

Polygenic Risk Score

Recruiting1 award1 criteria
This trial will test how well polygenic risk score testing works in patients who are at high genetic risk for certain diseases.
Image of University of Alabama at Birmingham Cancer Center in Birmingham, United States.

Quality-of-Life Assessment

Recruiting2 awardsPhase 3
This trial looks at how well patients stick to their medication plan when given text reminders and/or phone counseling.
Image of CBCC Global Research Inc., at Comprehensive Blood and Cancer Center in Bakersfield, United States.

Endocrine Therapy of Physician's Choice +1 More

Hormone Therapy

Recruiting2 awardsPhase 3
This trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Image of Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0028) in Marietta, United States.

Capecitabine +3 More

Antimetabolites

Recruiting2 awardsPhase 3
This trial will assess if pembrolizumab, when combined with chemotherapy, is more effective in treating hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer than chemotherapy alone. The primary hypotheses are that the combination of pembrolizumab and chemotherapy is superior to placebo and chemotherapy in regards to Progression-Free Survival (PFS) or overall survival (OS) in participants with programmed cell death-ligand 1 (PD-L1) combined positive score (CPS) ≥1 and ≥10.
Image of Carle Cancer Center in Urbana, United States.

Ribociclib +1 More

CDK4/6 Inhibitor

Recruiting4 awardsPhase 3
This trial will compare two treatments to find out which is better at prolonging progression-free survival in patients with advanced HER2-E and HR+/HER2- breast cancer.

Phase 3 Trials

Trials With No Placebo

View More Related Trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.